You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME

Methotrexate Metabolism and Its Relation to Clinical Effects: A Primer

  • Authors: Author: Joel M. Kremer, MD
  • THIS ACTIVITY HAS EXPIRED
Start Activity


Target Audience and Goal Statement

This activity is intended for rheumatologists and oncologists.

The goal of this activity is to educate physicians who use methotrexate in their patients about the metabolic pathways and influences on metabolism of methotrexate.

Upon completion of this activity, participants will be able to:

  1. List possible genetic variations in methotrexate metabolism.
  2. Enumerate influences of diet on methotrexate metabolism.
  3. Discuss the influence of metabolism of methotrexate on its efficacy and toxicity in rheumatic and oncologic diseases.


Disclosures

As an organization accredited by the ACCME, Medscape requires authors and editors to disclose any significant financial relationship during the past 12 months with the manufacturer of any product that may relate to the subject matter of the educational activity, whether or not the activity is commercially supported. Authors are also asked to disclose any mention of investigational products or unapproved uses of products regulated by the U.S. Food and Drug Administration.


Author(s)

  • Joel M. Kremer, MD

    Director of Research, The Center for Rheumatology, Clinical Professor of Medicine, Albany Medical College, Albany, New York; Director of Research, Albany Medical Center Hospital, Albany, New York

    Disclosures

    Disclosure: Joel M. Kremer, MD, has disclosed that he has received grant support and served as a consultant for Prometheus, Amgen, Abbott, Aventis, Centocor, and Merck. Dr. Kremer has disclosed that he discusses the unlabeled or investigational use of allopurinol to ameliorate methotrexate toxicity in this activity.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for a maximum of 1.5 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

CME

Methotrexate Metabolism and Its Relation to Clinical Effects: A Primer

Authors: Author: Joel M. Kremer, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

processing....

Substantial portions of this article are reproduced with permission of John Wiley & Sons, Inc. from: Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004;50:1370-1382. Copyright © 2004, American College of Rheumatology.

Introduction

In the 55 years since Farber[1] first described clinical remissions after use of the folate antagonist aminopterin for children with acute leukemia, methotrexate (MTX) has been used to treat millions of patients with both malignant and autoimmune diseases.[2] MTX is now the most widely prescribed disease-modifying antirheumatic drug (DMARD), used by at least 500,000 patients worldwide with rheumatoid arthritis. MTX is prescribed for more patients with rheumatoid arthritis than all of the biologic drugs in current use combined. It is the most commonly reported agent used in combination with other DMARDs, where clear additive therapeutic value is demonstrated.[2,3-9] The fear of severe organ-associated toxicity has abated with the development of guidelines for monitoring liver toxicity,[10] which has resulted in the virtual elimination of this problem, which had so frightened physicians and limited its earlier use. In addition, the recognition that MTX-associated pulmonary disease is most often a subacute syndrome associated with dry cough, often with dyspnea and fever,[11,12] has led to earlier recognition and avoidance of permanent lung sequelae in many patients receiving the drug. The realization that many of the gastrointestinal, bone marrow, and other toxicities, which so frequently limited its use prior to the 1980s, could be avoided by the routine use of folate supplementation,[13,14] has also given both clinicians and patients a heightened measure of security when prescribing this potent antimetabolite.

However, the overall level of sophistication regarding the many issues and complexities associated with the use of MTX is still often somewhat low. Many clinicians employ folic acid or folinic acid interchangeably without knowledge of differences in effects, while others may use MTX with a variety of other drugs in patients who may be at increased risk of adverse events due to significant drug interactions. Ideas and prescribing patterns associated with maximum weekly doses, use in the elderly, monitoring of blood tests, and when to "give up" and add other agents to be prescribed with MTX are often followed without specific rigorous scientific support.

It is apparent that very busy clinicians often do not have the time or resources to research and understand every publication describing the optimal, and sometimes subtle, mechanistic pathways that potentially can be used to support clinical decisions regarding the use of an agent like MTX.

It is the goal of this Clinical Update to review the major and significant relevant metabolic concepts associated with the use of MTX in patients with rheumatic disease, rather than to summarize publications of its clinical effects. A great deal of what we have learned about the metabolism of MTX is derived from the oncology literature, which is the source of a very large number of significant insights that are relevant to the manner in which rheumatologists use the drug in the treatment of rheumatic disease. Clinicians who are able to improve their familiarity with the metabolic, pharmacologic, and pharmacokinetic concepts presented should be better able to use the drug in a safer and more effective manner. It will also be seen that a newly emerging ability to routinely measure the effects of MTX on intracellular metabolites holds promise for predicting both efficacy and toxicity.